Funding agencies: Support for this project was provided by the Pharmaceutical Research and Manufacturers of America.
The current and projected economic burden of Parkinson's disease in the United States
Version of Record online: 21 FEB 2013
Copyright © 2012 Movement Disorders Society
Volume 28, Issue 3, pages 311–318, March 2013
How to Cite
Kowal, S. L., Dall, T. M., Chakrabarti, R., Storm, M. V. and Jain, A. (2013), The current and projected economic burden of Parkinson's disease in the United States. Mov. Disord., 28: 311–318. doi: 10.1002/mds.25292
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue online: 21 MAR 2013
- Version of Record online: 21 FEB 2013
- Manuscript Accepted: 21 OCT 2012
- Manuscript Revised: 4 OCT 2012
- Manuscript Received: 9 JUL 2012
- Parkinson's disease;
- economic burden;
- Parkinson's prevalence;
- disease cost
Parkinson's disease (PD), following Alzheimer's disease, is the second-most common neurodegenerative disorder in the United States. A lack of treatment options for changing the trajectory of disease progression, in combination with an increasing elderly population, portends a rising economic burden on patients and payers. This study combined information from nationally representative surveys to create a burden of PD model. The model estimates disease prevalence, excess healthcare use and medical costs, and nonmedical costs for each demographic group defined by age and sex. Estimated prevalence rates and costs were applied to the U.S. Census Bureau's 2010 to 2050 population data to estimate current and projected burden based on changing demographics. We estimate that approximately 630,000 people in the United States had diagnosed PD in 2010, with diagnosed prevalence likely to double by 2040. The national economic burden of PD exceeds $14.4 billion in 2010 (approximately $22,800 per patient). The population with PD incurred medical expenses of approximately $14 billion in 2010, $8.1 billion higher ($12,800 per capita) than expected for a similar population without PD. Indirect costs (e.g., reduced employment) are conservatively estimated at $6.3 billion (or close to $10,000 per person with PD). The burden of chronic conditions such as PD is projected to grow substantially over the next few decades as the size of the elderly population grows. Such projections give impetus to the need for innovative new treatments to prevent, delay onset, or alleviate symptoms of PD and other similar diseases. 2013 Movement Disorder Society